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Abstract
Background:	Cardiac	 tamponade	 is	a	serious	complication	of	catheter	ablation	for	
atrial	fibrillation	(AF).	However,	the	outcomes	of	catheter	ablation	in	patients	of	car-
diac	tamponade	are	unknown.
Methods:	We	performed	catheter	ablation	in	2467	sessions	of	AF	or	a	recurrence	of	
AF	between	 January	2007	and	 January	2016.	Of	 these,	 29	events	 in	27	patients	
(1.18%:	22	men;	64.5	±	10.4	years;	 17	with	paroxysmal	AF)	 of	 cardiac	 tamponade	
during	or	 after	 the	procedure	were	 recorded.	The	clinical	 characteristics	 and	out-
comes	of	these	29	events	were	studied	in	detail.
Results:	Of	the	19	events	where	the	ablation	procedure	was	completed,	seven	events	
developed	acute	recurrence	of	AF	(36.8%).	Of	the	10	events	with	an	incomplete	pro-
cedure,	10	exhibited	AF	recurrence	(100.0%).	Direct	oral	anticoagulants	were	used	in	
seven	events,	and	clinical	outcomes	were	not	significantly	different	compared	to	the	
remaining	21	events	that	were	prescribed	warfarin.	Pericarditis	occurred	in	10	events	
(34.5%)	after	the	procedure,	and	the	incidence	rate	was	lower	in	patients	receiving	
prophylactic	nonsteroidal	anti-	inflammatory	drugs	or	steroids	(2/15,	13.3%	vs	8/14,	
57.1%;	P	=	0.013).	Repeated	sessions	were	performed	in	12	events	(two	with	a	com-
plete	initial	procedure,	10	with	an	incomplete	initial	procedure).	Freedom	from	atrial	
arrhythmias	was	observed	 in	27	events	 (93.1%,	9	with	antiarrhythmic	drugs)	over	
midterm	follow-	up	(3.1	±	2.6	years).
Conclusion:	Although	cardiac	tamponade	caused	by	catheter	ablation	led	to	a	high	
rate	of	acute	AF	recurrence	and	pericarditis,	the	midterm	recurrence	rates	of	AF	are	
unaffected	if	the	procedure	can	be	completed.
K E Y W O R D S
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1  | INTRODUC TION
The	effectiveness	of	catheter	ablation	therapy	for	atrial	fibrilla-
tion	 (AF)	 is	well-	established.	However,	 for	maximum	 benefit,	 a	
reduction	 in	acute	procedure-	related	complications	 is	essential.	
In	recent	years,	the	number	of	AF	ablation	procedures	has	been	
increasing	worldwide.	Correspondingly,	the	incidence	of	cardiac	
tamponade,	a	serious	complication	of	catheter	ablation,	is	also	in-
creasing.	However,	there	is	little	midterm	follow-	up	research	on	
patients	of	cardiac	tamponade.	In	a	large	study,	major	complica-
tions	related	to	AF	ablation	occurred	in	4.54%-	6%	of	patients.1,2 
The	mortality	rate	associated	with	AF	ablation	was	0.15%,2 and 
cardiac	 tamponade	was	 the	most	 frequent	 cause	of	procedure-	
related death.3,4	The	incidence	rate	of	cardiac	tamponade	is	ap-
proximately	1%-	1.31%	but	subsequent	patient	outcomes	are	not	
clear.1,2,5	 Further,	 the	 use	 of	 direct	 oral	 anticoagulants	 (DOAC)	
has	 recently	 increased	 all	 over	 the	world.6	 The	 association	 be-
tween	this	change	in	anticoagulant	therapy	and	cardiac	tampon-
ade	 is	 still	 unclear.	 In	addition,	 although	pericarditis	 sometimes	
occurs	 alongside	 cardiac	 tamponade,	 the	 relationship	 between	
them	 remains	 poorly	 understood.	 Distinctive	 cases	 of	 delayed	
cardiac	tamponade	after	AF	ablation	have	also	been	reported,7-9 
TABLE  1 Clinical	characteristics	of	29	cardiac	tamponade	events
Event no Patient no Age (years) Sex BMI (kg/m2) AF type LAD (mm) LV- EF (%) Disease
Anticoagulant 
drug Antiplatelet drug Onset situation Pericardiocentesis
Drainage 
blood type
Drainage blood 
(mL)
1 1 63 M 24.7 PAF 37 72 — Warfarin — Left	atrium Done Venous 300
2 2 73 M 21.4 PAF 41 75 — Warfarin — Left	atrium Done Arterial 160
3 3 63 M 23.5 PAF 33 60 — Warfarin — Left	atrium Done Arterial 175
4 4 74 F 20.5 PAF 39 72 — Warfarin — Ward Done Venous 160
5 5 64 M 23.6 PerAF 41 69 — Warfarin Aspirin Left	atrium Done Venous 360
6 6 62 M 25.9 PAF 42 68 — Warfarin — Trans	septum Not	performed — —
7 7 75 F 22.5 PAF 40 68 — Dabigatran — Left	atrium Not	performed — —
8 8 64 M 27.7 PAF 43 72 — Warfarin — Left	atrium Not	performed — —
9 9 68 M 27.6 PAF 34 62 — Warfarin — Left	atrium Done Venous 500
10 10 65 M 21.9 LSPerAF 49 62 — Warfarin — Left	atrium Done Arterial 150
11 10 65 M 21.9 LSPerAF 49 62 — Warfarin — Left	atrium Done Arterial 250
12 11 42 M 28.0 PerAF 36 53 — Warfarin — Ward Done — —
13 12 70 M 22.7 PerAF 42 66 ASD	post	ope Warfarin — Trans	septum Done Arterial 250
14 13 59 M 16.4 PerAF 51 73 — Warfarin — Left	atrium Done Venous 500
15 14 67 M 24.4 PAF 41 64 — Warfarin — Left	atrium Done Arterial 160
16 15 42 M 22.7 PerAF 43 69 — Warfarin — Trans	septum Not	performed — —
17 16 76 M 24.0 PerAF 44 68 AR Warfarin — Ward Done Venous 200
18 17 51 F 28.5 PAF 34 66 — Warfarin — Ward Not	performed — —
19 18 49 F 26.9 PerAF 38 71 Funnel	chest Warfarin — Left	atrium Done Arterial 1000
20 19 65 M 24.5 PerAF 45 63 — Warfarin — After	discharge Done Venous 600
21 20 61 F 30.2 PAF 39 75 — Dabigatran — Left	atrium Done Venous 100
22 21 60 M 21.2 PAF 39 72 HOCM Dabigatran — Left	atrium Done Venous 350
23 22 64 M 26.7 LSPerAF 49 72 — Warfarin — Post	procedure Not	performed — —
24 23 73 F 19.1 PAF 37 60 HOCM Apixaban — Left	atrium Done Venous 250
25 24 80 F 22.0 PAF 39 68 — Not	use — Left	atrium Done Not	
mentioned
1300
26 25 70 M 28.8 PAF 48 70 — Warfarin — Left	atrium Not	performed — —
27 26 66 M 27.3 LSPerAF 42 69 — Rivaroxaban — Left	atrium Done Venous 300
28 27 76 M 23.0 PAF 48 77 VSA Rivaroxaban Clopidogrel Left	atrium Done Venous 1200
29 27 76 M 23.0 PAF 48 77 VSA Rivaroxaban Clopidogrel After	discharge Done Not	
mentioned
300
AF,	atrial	fibrillation;	AR,	aortic	regurgitation;	ASD	post	ope,	atrial	septal	defect	postsurgical	operation;	BMI,	body	mass	index;	Complete,	
procedure	could	be	completely	ended;	F,	female;	HOCM,	hypertrophic	obstructive	cardiomyopathy;	M,	male;	LAD,	left	atrial	diameter;	LSPerAF,	
long-	standing	persistent	AF;	LV-	EF,	left	ventricular-	ejection	fraction;	Not	use,	anticoagulant	drug	was	not	used	before	procedure;	Onset,	the	time	
that	cardiac	tamponade	occurred;	PAF,	paroxysmal	AF;	PerAF,	persistent	AF;	VSA,	vasospastic	angina.
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with	rupture	of	an	epicardial	hematoma	or	pericarditis	as	the	pos-
tulated	 causes.	 The	 aim	of	 this	 study	was	 to	 clarify	 the	 clinical	
characteristics	 and	midterm	 outcomes	 of	 patients	 with	 cardiac	
tamponade.
2  | METHODS
2.1 | Study participants
A	total	of	2467	sessions	in	which	patients	with	AF	and	atrial	tach-
ycardia	 (AT)	 related	 to	AF	 ablation,	 treated	with	 catheter	 ablation	
between	January	2007	and	January	2016,	were	retrospectively	en-
rolled	 in	 this	 study.	All	 arrhythmias	were	 resistant	 to	 at	 least	 one	
antiarrhythmic	 drug.	Of	 these	 patients,	 29	 events	 (22	males;	 age,	
64.5	±	10.4	year-	old;	 paroxysmal	 AF	 [PAF],	 17;	 Table	1)	 exhib-
ited	 cardiac	 tamponade	 during	 or	 after	 the	 procedure	 (29	 events,	
1.18%	of	 total	 cohort).	 PAF	was	 defined	 as	AF	 lasting	 7	 or	 fewer	
days,	and	persistent	atrial	fibrillation	(PerAF)	as	AF	lasting	>7	days.	
Long-	standing	persistent	atrial	fibrillation	(LSPerAF)	was	defined	as	
AF	persisting	for	>1	year.	The	recurrence	blanking	period	was	set	at	
3	months.	The	clinical	characteristics	of	the	29	events,	procedure-	
related	data,	acute	outcomes,	and	midterm	outcomes	were	examined	
TABLE  1 Clinical	characteristics	of	29	cardiac	tamponade	events
Event no Patient no Age (years) Sex BMI (kg/m2) AF type LAD (mm) LV- EF (%) Disease
Anticoagulant 
drug Antiplatelet drug Onset situation Pericardiocentesis
Drainage 
blood type
Drainage blood 
(mL)
1 1 63 M 24.7 PAF 37 72 — Warfarin — Left	atrium Done Venous 300
2 2 73 M 21.4 PAF 41 75 — Warfarin — Left	atrium Done Arterial 160
3 3 63 M 23.5 PAF 33 60 — Warfarin — Left	atrium Done Arterial 175
4 4 74 F 20.5 PAF 39 72 — Warfarin — Ward Done Venous 160
5 5 64 M 23.6 PerAF 41 69 — Warfarin Aspirin Left	atrium Done Venous 360
6 6 62 M 25.9 PAF 42 68 — Warfarin — Trans	septum Not	performed — —
7 7 75 F 22.5 PAF 40 68 — Dabigatran — Left	atrium Not	performed — —
8 8 64 M 27.7 PAF 43 72 — Warfarin — Left	atrium Not	performed — —
9 9 68 M 27.6 PAF 34 62 — Warfarin — Left	atrium Done Venous 500
10 10 65 M 21.9 LSPerAF 49 62 — Warfarin — Left	atrium Done Arterial 150
11 10 65 M 21.9 LSPerAF 49 62 — Warfarin — Left	atrium Done Arterial 250
12 11 42 M 28.0 PerAF 36 53 — Warfarin — Ward Done — —
13 12 70 M 22.7 PerAF 42 66 ASD	post	ope Warfarin — Trans	septum Done Arterial 250
14 13 59 M 16.4 PerAF 51 73 — Warfarin — Left	atrium Done Venous 500
15 14 67 M 24.4 PAF 41 64 — Warfarin — Left	atrium Done Arterial 160
16 15 42 M 22.7 PerAF 43 69 — Warfarin — Trans	septum Not	performed — —
17 16 76 M 24.0 PerAF 44 68 AR Warfarin — Ward Done Venous 200
18 17 51 F 28.5 PAF 34 66 — Warfarin — Ward Not	performed — —
19 18 49 F 26.9 PerAF 38 71 Funnel	chest Warfarin — Left	atrium Done Arterial 1000
20 19 65 M 24.5 PerAF 45 63 — Warfarin — After	discharge Done Venous 600
21 20 61 F 30.2 PAF 39 75 — Dabigatran — Left	atrium Done Venous 100
22 21 60 M 21.2 PAF 39 72 HOCM Dabigatran — Left	atrium Done Venous 350
23 22 64 M 26.7 LSPerAF 49 72 — Warfarin — Post	procedure Not	performed — —
24 23 73 F 19.1 PAF 37 60 HOCM Apixaban — Left	atrium Done Venous 250
25 24 80 F 22.0 PAF 39 68 — Not	use — Left	atrium Done Not	
mentioned
1300
26 25 70 M 28.8 PAF 48 70 — Warfarin — Left	atrium Not	performed — —
27 26 66 M 27.3 LSPerAF 42 69 — Rivaroxaban — Left	atrium Done Venous 300
28 27 76 M 23.0 PAF 48 77 VSA Rivaroxaban Clopidogrel Left	atrium Done Venous 1200
29 27 76 M 23.0 PAF 48 77 VSA Rivaroxaban Clopidogrel After	discharge Done Not	
mentioned
300
AF,	atrial	fibrillation;	AR,	aortic	regurgitation;	ASD	post	ope,	atrial	septal	defect	postsurgical	operation;	BMI,	body	mass	index;	Complete,	
procedure	could	be	completely	ended;	F,	female;	HOCM,	hypertrophic	obstructive	cardiomyopathy;	M,	male;	LAD,	left	atrial	diameter;	LSPerAF,	
long-	standing	persistent	AF;	LV-	EF,	left	ventricular-	ejection	fraction;	Not	use,	anticoagulant	drug	was	not	used	before	procedure;	Onset,	the	time	
that	cardiac	tamponade	occurred;	PAF,	paroxysmal	AF;	PerAF,	persistent	AF;	VSA,	vasospastic	angina.
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in	 detail.	 Ethical	 approval	was	 granted	 by	 the	 institutional	 review	
board	at	Tsukuba	University	Hospital.
2.2 | Ablation procedure and anticoagulation
Antiarrhythmic	 drugs	 were	 discontinued	 for	 at	 least	 five	 half-	
lives	 before	 the	 procedure,	 with	 the	 exception	 of	 amiodarone.	
Atrial	 thrombi	 were	 checked	 by	 transesophageal	 echocardiog-
raphy	on	 the	day	of	 (or	 the	day	before)	 the	procedure.	 Surface	
electrocardiography	 (ECG)	 and	 intracardiac	 electrograms	 were	
continuously	 displayed	 and	 stored	 on	 a	 computer-	based	 digital	
recording	 system	 using	 filter	 settings	 of	 30-	500	Hz	 during	 the	
procedure	(CardioLab	System;	Prucka	Engineering,	Houston,	TX,	
USA).	 In	 conventional	 radiofrequency	 catheter	 ablation	 (RFCA)	
cases,	 through	 a	 single	 transseptal	 puncture,	 a	 3.5	mm	 open-	
irrigated	 deflectable	 catheter	 (ThermoCool;	 Biosense	Webster,	
Diamond	Bar,	CA,	USA)	was	used	for	mapping	and	ablation.	The	
force-	sensing	ablation	catheter	(Smarttouch;	Biosense	Webster)	
was	 used	 if	 it	 was	 possible	 in	 terms	 of	 insurance-	related	 con-
cerns.	Radiofrequency	 (RF)	energy	was	delivered	at	 a	power	of	
20-	35	W,	maximum	 irrigation	 rate	of	30	mL/min,	 and	maximum	
temperature	 of	 42°C.	 The	 ipsilateral	 pulmonary	 vein	 (PV)	 was	
circumferentially	 ablated	 under	 3D	 mapping	 system	 guidance	
(CARTO;	Biosense	Webster;	or	Ensite	Navix;	St	Jude	Medical,	St.	
TABLE  2 Clinical	outcome	of	29	cardiac	tamponade	events
Event no Patient no Pericardiocentesis Drainage (days)
Hospital 
stay (days)
Complete 
procedure Procedure Contact force
Preventive  
administration Pericarditis Acute recurrence Redo
Midterm  
AF/AT control AF type Drug
1 1 Done 2 6 Yes PVI,	SVC No Yes No No No Yes PAF —
2 2 Done 3 12 No PVI Yes Yes No Yes Yes Yes PAF Propafenone
3 3 Done 2 8 Yes PVI No Yes No No No Yes PAF —
4 4 Done 2 13 Yes PVI,	CTI No Yes No Yes No Yes PAF Propafenone
5 5 Done 2 10 Yes PVI,	roof No Yes No No No Yes PerAF Bepridil
6 6 Not	performed — 7 No C.T.	occurred	before	PVI No Yes No Yes Yes Yes PAF —
7 7 Not	performed — 10 Yes PVI Yes Yes No No No Yes PAF —
8 8 Not	performed — 5 No C.T.	occurred	before	PVI No Yes No Yes Yes Yes PAF —
9 9 Done 3 13 Yes PVI,	CTI No No No No No Yes PAF —
10 10 Done 2 7 No PVI No No No Yes Yes Yes LSPerAF Amiodarone
11 10 Done 3 4 Yes PVI No No No No No Yes LSPerAF Amiodarone
12 11 Done 0 9 No PVI No Yes No Yes Yes Yes PerAF —
13 12 Done 3 11 Yes PVI Yes Yes No Yes No No PerAF Amiodarone
14 13 Done 2 40 No C.T.	occurred	before	PVI No No No Yes Yes No PerAF Amiodarone
15 14 Done 2 12 No C.T.	occurred	before	PVI No No Yes Yes Yes Yes PAF —
16 15 Not	performed — 15 No C.T.	occurred	before	PVI No No Yes Yes Yes Yes PerAF —
17 16 Done 2 14 Yes PVI,	CTI No No Yes Yes No Yes PerAF Amiodarone
18 17 Not	performed — 18 Yes PVI,	SVC,	CTI No No Yes Yes No Yes PAF —
19 18 Done 1 14 Yes PVI Yes No Yes No No Yes PerAF —
20 19 Done 5 10 Yes PVI,	CFAE,	roof,	CTI Yes No Yes No No Yes PerAF —
21 20 Done 2 6 No PVI,	CTI Yes No No Yes Yes Yes PAF —
22 21 Done 3 7 Yes PVI,	CTI Yes Yes No Yes Yes Yes PAF Amiodarone
23 22 Not	performed — 4 Yes PVI,	roof,	CTI Yes No No Yes Yes Yes LSPerAF Amiodarone
24 23 Done 0 7 Yes Cryoballon,	CTI No Yes No No No Yes PAF —
25 24 Done 3 22 Yes PVI Yes Yes Yes Yes No Yes PAF —
26 25 Not	performed — 13 No C.T.	occurred	before	PVI No Yes Yes Yes Yes Yes PAF —
27 26 Done 2 6 Yes PVI,	CTI Yes No Yes No No Yes LSPerAF Amiodarone
28 27 Done 4 19 Yes Cryoballon No No Yes No No Yes PAF —
29 27 Done 4 14 Yes C.T.	occurred	before	PVI No Yes No No No Yes PAF —
AF,	atrial	fibrillation;	AT,	atrial	tachycardia;	CFAE,	complex	fractionated	atrial	electrogram;	CTI,	cavo	tricuspid	isthmus	line	ablation;	C.T.	occurred	
before	PVI,	cardiac	tamponade	occurred	before	pulmonary	vein	isolation;	LSPerAF,	long-	standing	persistent	atrial	fibrillation;	PAF,	paroxysmal	atrial	
fibrillation;	PerAF,	persistent	atrial	fibrillation;	PVI,	pulmonary	vein	isolation;	roof,	left	atrium	roof	liner	ablation;	SVC,	superior	vena	cava;	Redo,
redo	AF/AT	ablation	session.
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Paul,	 MN,	 USA).	 In	 cryoballoon	 cases,	 a	 steerable	 15	F	 sheath	
(Flexcath®;	Medtronic	Inc.,	Minneapolis,	MN,	USA)	was	used	and	
flushed	continuously	with	heparinized	saline.	A	mapping	catheter	
(Achieve®;	Medtronic	 Inc.)	was	 advanced	 into	 each	PV,	 and	PV	
antrum	occlusion	was	considered.	Following	angiography,	a	sin-
gle	3	min	application	was	performed	using	a	second-	generation	
cryoballoon	 (28	mm	 Advance	 balloon;	 Medtronic	 Inc)	 in	 each	
targeted	 PV.	 In	 some	 cases	 of	 PerAF	 and	 LSPerAF,	 a	 left	 atrial	
roof	line,	superior	vena	cave	isolation,	and	complex	fractionated	
atrial	 electrogram	 ablation	were	 added	 at	 the	 discretion	 of	 the	
operator.	If	AT	occurred	after	intravenous	injection	of	isoproter-
enol	and/or	programmed	atrial	stimulation	and	incremental	burst	
pacing	 from	 the	 catheter	 at	 the	 top	 of	 the	 right	 atrium,	 it	 was	
treated accordingly.
Anticoagulant	therapy	was	prescribed	before	catheter	ablation.	
The	attending	physician	selected	the	appropriate	anticoagulant	drug	
depending	on	age	and	renal	function.	Anticoagulant	drugs	were	cho-
sen	among	warfarin	or	factor	Xa	inhibitors	(apixaban,	edoxaban,	ri-
varoxaban)	or	direct	oral	thrombin	inhibitors	(dabigatran	etexilate).	
In	 the	 case	of	warfarin,	 the	 target	 prothrombin	 time-	international	
normalized	 ratio	 (PT-	INR)	 was	 set	 to	 2.0-	3.0	 in	 patients	 younger	
than	70	years	and	1.6-	2.6	in	those	older	than	70	years.10	All	patients	
underwent	 catheter	 ablation	 without	 interruption	 of	 warfarin	 or	
DOAC.	Immediately	following	the	transseptal	puncture,	5000	units	
TABLE  2 Clinical	outcome	of	29	cardiac	tamponade	events
Event no Patient no Pericardiocentesis Drainage (days)
Hospital 
stay (days)
Complete 
procedure Procedure Contact force
Preventive  
administration Pericarditis Acute recurrence Redo
Midterm  
AF/AT control AF type Drug
1 1 Done 2 6 Yes PVI,	SVC No Yes No No No Yes PAF —
2 2 Done 3 12 No PVI Yes Yes No Yes Yes Yes PAF Propafenone
3 3 Done 2 8 Yes PVI No Yes No No No Yes PAF —
4 4 Done 2 13 Yes PVI,	CTI No Yes No Yes No Yes PAF Propafenone
5 5 Done 2 10 Yes PVI,	roof No Yes No No No Yes PerAF Bepridil
6 6 Not	performed — 7 No C.T.	occurred	before	PVI No Yes No Yes Yes Yes PAF —
7 7 Not	performed — 10 Yes PVI Yes Yes No No No Yes PAF —
8 8 Not	performed — 5 No C.T.	occurred	before	PVI No Yes No Yes Yes Yes PAF —
9 9 Done 3 13 Yes PVI,	CTI No No No No No Yes PAF —
10 10 Done 2 7 No PVI No No No Yes Yes Yes LSPerAF Amiodarone
11 10 Done 3 4 Yes PVI No No No No No Yes LSPerAF Amiodarone
12 11 Done 0 9 No PVI No Yes No Yes Yes Yes PerAF —
13 12 Done 3 11 Yes PVI Yes Yes No Yes No No PerAF Amiodarone
14 13 Done 2 40 No C.T.	occurred	before	PVI No No No Yes Yes No PerAF Amiodarone
15 14 Done 2 12 No C.T.	occurred	before	PVI No No Yes Yes Yes Yes PAF —
16 15 Not	performed — 15 No C.T.	occurred	before	PVI No No Yes Yes Yes Yes PerAF —
17 16 Done 2 14 Yes PVI,	CTI No No Yes Yes No Yes PerAF Amiodarone
18 17 Not	performed — 18 Yes PVI,	SVC,	CTI No No Yes Yes No Yes PAF —
19 18 Done 1 14 Yes PVI Yes No Yes No No Yes PerAF —
20 19 Done 5 10 Yes PVI,	CFAE,	roof,	CTI Yes No Yes No No Yes PerAF —
21 20 Done 2 6 No PVI,	CTI Yes No No Yes Yes Yes PAF —
22 21 Done 3 7 Yes PVI,	CTI Yes Yes No Yes Yes Yes PAF Amiodarone
23 22 Not	performed — 4 Yes PVI,	roof,	CTI Yes No No Yes Yes Yes LSPerAF Amiodarone
24 23 Done 0 7 Yes Cryoballon,	CTI No Yes No No No Yes PAF —
25 24 Done 3 22 Yes PVI Yes Yes Yes Yes No Yes PAF —
26 25 Not	performed — 13 No C.T.	occurred	before	PVI No Yes Yes Yes Yes Yes PAF —
27 26 Done 2 6 Yes PVI,	CTI Yes No Yes No No Yes LSPerAF Amiodarone
28 27 Done 4 19 Yes Cryoballon No No Yes No No Yes PAF —
29 27 Done 4 14 Yes C.T.	occurred	before	PVI No Yes No No No Yes PAF —
AF,	atrial	fibrillation;	AT,	atrial	tachycardia;	CFAE,	complex	fractionated	atrial	electrogram;	CTI,	cavo	tricuspid	isthmus	line	ablation;	C.T.	occurred	
before	PVI,	cardiac	tamponade	occurred	before	pulmonary	vein	isolation;	LSPerAF,	long-	standing	persistent	atrial	fibrillation;	PAF,	paroxysmal	atrial	
fibrillation;	PerAF,	persistent	atrial	fibrillation;	PVI,	pulmonary	vein	isolation;	roof,	left	atrium	roof	liner	ablation;	SVC,	superior	vena	cava;	Redo,
redo	AF/AT	ablation	session.
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of	 intravenous	heparin	were	given	and	heparinized	 saline	was	 ad-
ministered	via	sustained	injection	to	maintain	the	activated	clotting	
time	 at	 300-	400	s.	 Atrial	 blood	 pressure	 was	monitored	 continu-
ously	from	the	4	Fr	sheath	positioned	within	the	right	femoral	artery.
2.3 | Definition of arrhythmia, cardiac 
tamponade, and pericarditis
Atrial	arrhythmias	were	defined	as	supraventricular	arrhythmias	
related	 to	AF	 ablation,	 such	 as	 focal	 or	macro-	reentrant	 tachy-
cardia	at	the	left	atrium.	Common	atrial	flutter	in	the	right	atrium	
was	excluded	from	this	definition	in	this	study.	AF	or	AT	related	to	
prior	AF	ablation	was	assumed	to	be	sustained	for	more	than	2	h.	
Cardiac	tamponade	was	defined	as	an	 increase	 in	pericardial	ef-
fusion	of	>5	mm,	a	sign	of	collapse	in	the	atrium	or	ventricle,	and	
a	decrease	in	systolic	blood	pressure	to	<80	mm	Hg.	Pericarditis	
was	defined	by	both	an	increase	in	pericardial	effusion	of	>5	mm	
at	 onset	 of	 cardiac	 tamponade	 and	 ST	 elevation	 >2	mm	 on	 >6	
leads.
2.4 | Diagnosis and management of 
cardiac tamponade
If	 cardiac	 tamponade	 was	 suspected	 due	 to	 a	 decrease	 in	 blood	
pressure	 or	 unexpected	 catheter	manipulation,	 the	motion	 of	 the	
cardiac	 silhouette	 was	 checked	 in	 the	 left	 anterior	 oblique	 view.	
Pericardial	effusion	was	confirmed	by	transthoracic	or	intracardiac	
echocardiography.	When	 cardiac	 tamponade	was	 confirmed,	 peri-
cardiocentesis	 was	 performed	 under	 the	 guidance	 of	 fluoroscopy	
and	ultrasonography	from	the	left	sternal,	apical,	or	subxiphoid	po-
sitions.	Seven	events	immediately	recovered	from	hypotensive	epi-
sodes	after	transvenous	injection	of	noradrenalin	and	extracellular	
fluid;	therefore,	observational	therapy	was	selected.	A	pigtail	cathe-
ter	was	introduced	into	the	pericardial	space	and	the	pericardial	fluid	
was	drained.	The	drained	blood	was	subjected	to	blood	gas	analysis	
to	determine	the	presence	of	atrial	or	venous	blood.	The	pericardial	
fluid	was	manually	drained	and	connected	to	a	closed	drainage	sys-
tem.	Heparin	and	warfarin	were	neutralized	using	protamine	sulfate	
and	vitamin	K.	The	dabigatran	neutralizer	was	not	used	in	this	study	
and	 the	 other	 DOAC	 do	 not	 have	 neutralizers,	 while	 all	 patients	
treated	with	warfarin	received	a	vitamin	K	neutralizer.	The	patients	
were	managed	in	the	intensive	care	unit	while	the	drainage	catheter	
was	within	the	pericardial	space.	After	pericardial	fluid	flow	stopped,	
the	drainage	catheter	was	removed	and	oral	anticoagulant	therapy	
was	resumed.
2.5 | Definition of acute outcome, midterm 
outcome, AF/AT control, and follow- up
“Acute	 recurrence”	 was	 defined	 as	 AF/AT	 recurrence	 during	 the	
hospital	 stay	 for	 catheter	 ablation.	 “Midterm	 recurrence”	 was	 de-
fined	 as	AF/AT	 recurrence	while	 the	patient	was	being	 followed	 in	
the	outpatient	clinic	or	after	any	 required	 repeat	procedures.	After	
discharge,	 patients	 were	 followed	 at	 2	weeks,	 1,	 3,	 6	months,	 and	
every	6	months	thereafter	at	an	outpatient	clinic.	Recurrences	were	
investigated	according	to	subjective	symptoms,	12-	lead	ECG,	Holter	
ECG	(DSC-	3300;	Nihon	Kohden,	Tokyo,	Japan),	and	an	event	recorder	
(HCG-	901;	Omron,	Kyoto,	Japan).	Antiarrhythmic	drugs	were	discon-
tinued	after	catheter	ablation	at	the	discretion	of	the	attending	physi-
cian	with	input	from	the	patient.	“AF/AT	control”	was	defined	as	the	
maintenance	of	sinus	rhythm	with	or	without	antiarrhythmic	drugs.
2.6 | Statistical analyses
Continuous	variables	are	presented	as	means	±	1	standard	deviation,	
and	 skewed	 variables	 are	 expressed	 as	medians	with	 interquartile	
ranges.	 Student’s	 t	 test	 or	 the	 Mann-	Whitney	 U	 tests	 were	 per-
formed	for	two-	group	comparisons	of	continuous	variables,	as	per	
F IGURE  1 The	results	of	the	acute	and	
midterm	recurrence	of	catheter	ablation	
in	patients	with	cardiac	tamponade.	AAD,	
antiarrhythmic	drug;	AF,	atrial	fibrillation;	
AT,	atrial	tachycardia;	Complete	Ablation,	
procedure	was	completed;	Incomplete	
Ablation,	procedure	could	not	be	
completed;	No	recur,	AF	and	AT	did	not	
recur;	Recur,	AF	or	AT	recurred;	S.R.,	sinus	
rhythm
17/29 events:
AF/AT Recur (58.6%)
29 events:
Cardiac tamponade
10 events: 
Incomplete ablaon (34.5%)
19 events: 
Complete ablaon (65.5%)
27/29 events: S.R. 
(93.1%; 9 with AAD) 
2 events Redo
12 events: S.R. 
(100%; 4 with AAD)
10 events Redo 
10 events
Recur (100%)
12 events
No recur (63.1%)
7 events
Recur (36.8%)
in acute term
in mid term
12 redo session
9 events: S.R.
(90.0%; 2 with AAD)
6 events: S.R. 
(85.7%; 3 with AAD)
in acute term
in mid term
18/19 events: S.R.
(94.7%; 7 with AAD)
9/10 events: S.R.
(90.0%; 2 with AAD)
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the	normality	of	 the	data	distribution.	The	chi-	squared	or	Fisher’s	
exact	test	was	used	for	two-	group	comparisons	of	categorical	vari-
ables.	Differences	were	reported	as	significant	if	P	<	0.05.	All	statis-
tical	analyses	were	performed	using	SPSS	(version	16.0;	SPSS	Inc.,	
Chicago,	IL,	USA).
3  | RESULTS
3.1 | Patients’ characteristics
This	 study	 included	 27	 patients	 (29	 events;	 64.5	±	10.4	years;	 22	
men;	body	mass	index,	24.2	±	3.2	kg/m2;	Table	1)	with	cardiac	tam-
ponade	 related	 to	 AF	 ablation.	 The	mean	 left	 atrial	 diameter	was	
41.6	±	5.0	mm	and	 the	mean	 left	 ventricular-	ejection	 fraction	was	
68.1	±	5.6%.	Oral	anticoagulant	therapy	was	being	administered	for	
at	least	1	month	before	catheter	ablation	in	26	patients.	Structurally	
normal	hearts	were	observed	 in	23	patients	while	one	had	under-
gone	patch	closure	of	an	atrial	 septum	defect,	one	was	diagnosed	
with	mild	to	moderate	aortic	regurgitation	on	echocardiography,	and	
two	exhibited	hypertrophic	obstructive	cardiomyopathy	(Table	1).
3.2 | Causes of cardiac tamponade
Cardiac	tamponade	was	caused	by	intracardiac	catheter	manipula-
tion	 in	 25	 events	 (25/29;	 86.2%),	 atrial	 septum	 puncture	 in	 three	
(3/29;	10.3%),	and	postprocedural	inflammation	in	two	(2/29;	6.9%).	
Regarding	 the	 timing	of	cardiac	 tamponade	occurrence,	23	events	
(23/29;	 79.3%)	 occurred	 during	 ablation	 in	 the	 electrophysiology	
Demographic variables
All events 
n = 28a
Warfarin Group 
n = 21
DOAC Group 
n = 7 P
Age	(y	±	SD) 64.4	±	9.30 62.7	±	9.44 69.6	±	7.10 0.088
Male,	n 22/28	(78.6%) 18/21	(85.7%) 4/7	(57.1%) 0.111
BMI	(kg/m2) 24.2	±	3.22 24.4	±	3.10 23.8	±	3.76 0.658
PAF,	n 16/28	(57.1%) 10/21	(47.6%) 6/7	(85.7%) 0.078
LAD	(mm) 41.9	±	5.08 41.9	±	5.37 41.9	±	4.45 1.000
LV-	EF	(%) 68.1	±	5.74 67.1	±	5.39 71.1	±	6.10 0.108
Onset	situations
EP	lab,	n 22/28	(78.6%) 16/21	(76.2%) 6/7	(85.7%) 0.595
Ward,	n 4/28	(14.3%) 4/21	(19.0%) 0/7	(0.0%) 0.212
Blood	typeb
Venous	blood,	n 12/19	(63.2%) 7/14	(50.0%) 5/5	(100%) 0.047*
Atrial	blood,	n 7/19	(36.8%) 7/14	(50.0%) 0/5	(0.0%) 0.047*
Pericardiocentesis,	n 22/28	(78.6%) 16/21	(76.2%) 6/7	(85.7%) 0.595
Hospital	stay	(days) 11.2	±	6.94 11.7	±	7.53 9.9	±	4.95 0.560
Drainage	blood	(mL) 363	±	286	
(n	=	20)
340	±	240	
(n	=	14)
417	±	393	
(n	=	6)
0.598
Complete	procedure,	n 18/28	(64.3%) 12/21	(57.1%) 6/7	(85.7%) 0.172
Preventive	 
administration,	n
14/28	(50.0%) 10/21	(47.6%) 4/7	(57.1%) 0.662
Pericarditis,	n 9/28	(32.1%) 7/21	(33.3%) 2/7	(28.6%) 0.815
Acute	recurrence,	n 16/28	(57.1%) 14/21	(66.7%) 2/7	(28.6%) 0.078
Midterm	recurrence,	n 2/28	(7.1%) 2/21	(9.5%) 0/7	(0.0%) 0.397
Pre	CRP	(mg/dL) 0.42	±	1.69 0.09	±	0.12 1.41	±	3.35 0.071
Max	CRP	(mg/dL) 6.71	±	6.66 6.24	±	6.47 8.11	±	7.52 0.530
Acute	recurrence,	AF/AT	recurrence	in	acute	term;	AF,	atrial	fibrillation;	AT,	atrial	tachycardia;	BMI,	
body	mass	 index;	Complete	procedure,	procedure	could	be	completely	ended;	DOAC,	direct	oral	
anticoagulants;	EP,	electrophysiological;	Hospital	stay,	the	length	of	hospitalization;	LAD,	left	atrial	
diameter;	LV-	EF,	left	ventricular-	ejection	fraction;	Max	CRP,	the	maximum	value	of	serum	C-	reactive	
protein;	Midterm	AF/AT	control;	AF/AT	control	 in	midterm;	PAF,	paroxysmal	atrial	fibrillation;	Pre	
CRP,	the	preoperative	serum	C-	reactive	protein;	Preventive	administration,	preventive	administra-
tion	for	pericarditis;	SD,	standard	deviation.
aThe	number	of	the	patients	who	took	anticoagulant	was	28,	as	one	patient	did	not	take	it	before	
catheter	ablation.	
bThe	number	of	this	event	was	19	of	28,	as	the	drainage	was	not	performed	in	seven,	and	the	drain-
age	blood	type	could	not	be	evaluated	in	the	remaining	two	events.	
*P	<	0.05.	
TABLE  3 Comparison	of	clinical	
characteristics	between	warfarin	group	
and	DOAC	group
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suite,	four	(4/29;	13.8%)	during	the	ward	stay	after	the	procedure,	
and	two	events	(2/29;	6.9%)	at	10	and	33	days	postprocedure.	In	19	
events	 (19/29,	 65.5%)	 the	 ablation	procedure	was	 completed,	 and	
in	10	(10/29,	34.5%)	it	could	not	be	completed	on	the	first	attempt.	
There	 were	 no	 instances	 of	 cardiac	 tamponade	 associated	 with	
steam	pops.
3.3 | Management of cardiac tamponade
Percutaneous	pericardial	puncture	was	performed	in	21	events	and	
seven	 events	 underwent	 conservative	 treatment	 without	 punc-
ture.	 In	one	event,	 the	puncture	 could	not	be	performed	because	
of	 anatomical	 difficulties	 (Event	 12;	 Table	2).	 The	 average	 volume	
of	initially	drained	blood	was	408	±	345	mL	(21	events;	range,	100-	
1300	mL;	Table	1)	and	the	drain	pigtail	catheter	was	placed	for	an	
average	 of	 2.5	±	1.1	days	 (20	 events;	 range,	 0-	5	days;	 Table	2).	 In	
seven	events	(36.8%;	7/19),	blood	gas	analysis	showed	atrial	blood	
and	12	events	 (63.2%;	12/19)	 showed	venous	blood.	The	hospital	
stay	 was	 11.6	±	7.1	days	 (range,	 4-	40	days).	 No	 patients	 died	 or	
required	 surgical	 repairs	 and	 all	 patients	were	 discharged	 to	 their	
homes.
3.4 | Acute and midterm recurrence
The	results	of	the	acute	and	midterm	recurrence	of	catheter	ablation	
in	patients	with	cardiac	tamponade	are	shown	in	Figure	1.	Among	the	
19	events	of	cardiac	tamponade,	in	which	catheter	ablation	was	com-
pleted,	seven	events	developed	acute	recurrence	of	AF	or	AT	(7/19,	
36.8%;	Table	2).	Repeat	sessions	were	performed	in	the	10	events	in	
which	the	procedure	was	not	completed	and	in	two	in	which	there	was	
TABLE  4 Comparison	of	clinical	characteristics	between	pericarditis	group	and	nonpericarditis	group
Demographic variables
All events 
n = 29
Pericarditis group 
n = 10
Nonpericarditis group 
n = 19 P value
Age	(y	±	SD) 64.5	±	10.4 64.2	±	12.8 65.3	±	7.8 0.771
Male,	n 22/29	(75.9%) 7/10	(70.0%) 15/19	(78.9%) 0.593
BMI	(kg/m2) 24.2	±	3.2 25.2	±	2.5 23.6	±	3.4 0.203
PAF,	n 17/29	(58.6%) 5/10	(50.0%) 12/19	(63.2%) 0.494
LAD	(mm) 41.6	±	5.0 42.2	±	4.4 41.5	±	5.4 0.738
LV-	EF	(%) 68.1	±	5.6 68.5	±	3.9 67.9	±	6.5 0.789
Anticoagulant	drugs
Warfarin	use,	n 21/29	(72.4%) 7/10	(70.0%) 14/19	(73.7%) 0.833
DOAC	use,	n 7/29	(24.1%) 2/10	(20.0%) 5/19	(26.3%) 0.766
Onset	situations
EP	lab,	n 23/29	(79.3%) 7/10	(70.0%) 16/19	(84.2%) 0.369
Ward,	n 4/29	(13.8%) 2/10	(20.0%) 2/19	(10.5%) 0.482
Blood	typea
Venous	blood,	n 12/19	(63.2%) 4/6	(66.7%) 8/13	(61.5%) 0.829
Atrial	blood,	n 7/19	(36.8%) 2/6	(33.3%) 5/13	(38.5%) 0.829
Pericardiocentesis,	n 22/29	(75.9%) 7/10	(70.0%) 15/19	(78.9%) 0.593
Hospital	stay	(days) 11.6	±	7.1 14.3	±	4.6 10.2	±	7.8 0.0048**
Drainage	blood	(mL) 408	±	345	(n	=	21) 680	±	485	(n	=	7) 272	±	124	(n	=	14) 0.071
Complete	procedure,	n 19/29	(65.5%) 7/10	(70.0%) 12/19	(63.2%) 0.713
Preventive	administration,	n 15/29	(51.7%) 2/10	(20.0%) 13/19	(68.4%) 0.013*
Acute	recurrence,	n 17/29	(58.6%) 6/10	(60.0%) 11/19	(57.9%) 0.913
Midterm	recurrence,	n 2/29	(6.9%) 0/10	(0.0%) 2/19	(10.5%) 0.288
Pre	CRP	(mg/dL) 0.41	±	1.7 0.11	±	0.1 0.56	±	2.5 0.498
Max	CRP	(mg/dL) 6.68	±	6.5 12.32	±	7.8 3.71	±	3.0 0.0002**
Acute	recurrence,	AF/AT	recurrence	in	acute	term;	AF,	atrial	fibrillation;	AT,	atrial	tachycardia;	BMI,	body	mass	index;	Complete	procedure,	procedure	
could	be	completely	ended;	DOAC,	direct	oral	anticoagulants;	EP,	electrophysiological;	Hospital	stay,	the	length	of	hospitalization;	LAD,	left	atrial	di-
ameter;	LV-	EF,	left	ventricular-	ejection	fraction;	Max	CRP,	the	maximum	value	of	serum	C-	reactive	protein;	Midterm	AF/AT	control;	AF/AT	control	in	
midterm;	PAF,	paroxysmal	atrial	fibrillation;	Pre	CRP,	the	preoperative	serum	C-	reactive	protein;	Preventive	administration,	preventive	administration	
for	pericarditis;	SD,	standard	deviation.
aThe	number	of	this	event	was	19	of	29,	as	the	drainage	was	not	performed	in	seven,	and	the	drainage	blood	type	could	not	be	evaluated	in	the	remain-
ing	three	events.
*P	<	0.05;	**P	<	0.005.
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AF/AT	recurrence	over	blanking	periods	of	3	months.	Optimal	medical	
therapy	was	administered	in	11	events	(37.9%,	11/29;	3	PAF,	4	PerAF,	
4	LSPerAF;	Table	2)	at	the	discretion	of	the	attending	physician	in	con-
sultation	with	the	patient.	By	midterm	follow-	up	(3.1	±	2.6	years),	27	
of	29	events	were	free	from	AF	or	AT	(nine	with	medication).	Other	
major	complications	such	as	death,	congestive	heart	failure,	or	stroke	
were	not	observed	during	the	follow-	up	period.
3.5 | Anticoagulant therapy
Anticoagulant	therapy	was	administered	in	28	events	(96.6%)	be-
fore	catheter	ablation	(Table	1).	Among	them,	21	events	received	
warfarin,	 and	 seven	 events	 received	 factor	Xa	 inhibitors	 (apixa-
ban,	 edoxaban,	 rivaroxaban)	 or	 direct	 oral	 thrombin	 inhibitors	
(dabigatran	etexilate).	There	was	no	significant	difference	 in	 the	
clinical	 characteristics	 and	 outcomes	 between	 the	warfarin	 and	
DOAC	groups.	No	significant	differences	in	drained	blood	volume	
(warfarin	 group,	 340	±	240	mL	 vs	 DOAC	 group,	 417	±	393	mL;	
P	=	0.598)	and	hospital	stay	(warfarin	group,	11.7	±	7.53	days,	vs	
DOAC	group,	9.9	±	4.95	days;	P	=	0.560)	were	observed.	Only	the	
rate	 of	 venous	 blood	 tamponade	was	 significantly	 higher	 in	 the	
DOAC	group	[5/5	(100%)	vs	7/14	(50.0%);	P	=	0.047;	Table	3].	The	
acute	and	midterm	recurrence	rates	of	AF	were	not	significantly	
different	(Table	3).
3.6 | Pericarditis associated with cardiac tamponade
Among	all	29	events,	10	 (10/29;	34.5%)	developed	pericarditis.	
Most	 cases	 of	 pericarditis	 developed	 immediately	 after	 cardiac	
tamponade;	 however,	 one	 developed	 after	 discharge	 from	 the	
hospital	 (Table	2;	Event	20).	Patients	with	pericarditis	exhibited	
more	 severe	disease	 statuses	 than	 those	without	 (Table	4).	The	
maximum	 C-	reactive	 protein	 values	 were	 higher	 in	 the	 cardiac	
tamponade	with	pericarditis	group	than	in	the	cardiac	tamponade	
without	 pericarditis	 group	 (12.32	±	7.8	 vs	 3.71	±	3.0	mg/dL;	
P	=	0.0002).	 The	 mean	 hospitalization	 was	 also	 longer	 in	 the	
pericarditis	 group	 (14.3	±	4.6	vs	10.2	±	7.8	days;	P	=	0.0048).	 In	
contrast,	there	was	no	statistically	significant	difference	in	mid-
term	outcome	between	 the	 two	 groups	 (with	 pericarditis,	 0/10	
events,	 0.0%;	 without	 pericarditis	 group,	 2/19	 events,	 10.5%;	
P	=	0.288).	 Anti-	inflammatory	 drugs,	 such	 as	 nonsteroidal	 anti-	
inflammatories	(NSAIDs),	or	steroids	were	administered	at	the	at-
tending	physician’s	discretion	in	15	events	to	prevent	pericarditis	
(Table	2).	The	amount	of	blood	drained	in	the	pericarditis	group	
was	higher	than	that	in	the	nonpericarditis	group	(680	±	485	mL	
vs	 272	±	124	mL;	 P	=	0.071).	 The	 incidence	 rate	 of	 pericarditis	
was	lower	in	the	group	that	received	prophylactic	treatment	than	
in	 the	 group	 that	 did	 not	 (2/15	 events,	 13.3%	 vs	 8/14	 events,	
57.1%;	 P	=	0.013;	 odds	 ratio,	 0.115;	 95%	 confidence	 intervals,	
0.019-	0.717).
3.7 | Delayed tamponade
In	 this	 study,	 only	 two	 events	 developed	 delayed	 tamponade	
(2/2467,	0.081%).	In	one	event,	the	patient	noticed	chest	discom-
fort	 10	days	 after	 catheter	 ablation.	He	 visited	 the	 emergency	
room	after	discharge	and	pericardial	effusion	was	confirmed	via	
echocardiography	 (Figure	2A).	 After	 pericardiocentesis,	 there	
was	 no	 reaccumulation	 of	 effusion.	 In	 another	 event,	 cardiac	
tamponade	occurred	immediately	after	PV	isolation	by	cryobal-
loon	and	pericardiocentesis	was	performed	at	once.	Pericarditis	
occurred	2	days	after	catheter	ablation.	NSAIDs	and	colchicine	
were	 prescribed,	 and	 after	 resolution	 of	 the	 pericarditis,	 the	
patient	 was	 discharged.	 However,	 33	days	 after	 catheter	 abla-
tion,	 he	 experienced	 new-	onset	 dyspnea	 and	 presented	 to	 the	
emergency	 department.	 We	 observed	 increased	 pericardial	
fluid	 and	 inflow	 blockage	 on	 the	 echocardiogram,	 diagnosed	
him	with	 recurrent	 cardiac	 tamponade	and	performed	a	 repeat	
F IGURE  2 A,	A	case	of	delayed	tamponade	(event	20).	This	figure	shows	the	transthoracic	echocardiography	(parasternal,	long-	axis	view)	
10	days	after	catheter	ablation.	Moderate	pericardial	effusion	(white	arrow)	was	observed	as	a	12	mm	thickness	around	the	heart.	B,	An	
electrocardiogram	(ECG)	of	pericarditis	(event	16).	In	this	patient,	atrial	fibrillation	(AF)	recurred	with	development	of	pericarditis
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pericardiocentesis.	 The	 ST	 elevation	 on	 ECG	 and	 increased	
serum	C-	reactive	 protein	 levels	 supported	 the	 diagnosis	 of	 re-
current	pericarditis.
4  | DISCUSSION
4.1 | Main findings
To	 the	 best	 of	 our	 knowledge,	 this	 study	 describes	 the	 longest	
follow-	up	 period	 for	 patients	 with	 cardiac	 tamponade	 associ-
ated	with	ablation	for	AF.	 In	addition,	only	a	few	reports	have	de-
scribed	 pericarditis	 in	 patients	 with	 cardiac	 tamponade	 and	 the	
relationship	 between	 DOAC	 and	 cardiac	 tamponade.	 Among	 the	
patients	with	cardiac	tamponade	in	our	study,	seven	events	(24.1%)	
were	 prescribed	 DOAC.	 The	 acute	 and	 midterm	 recurrence	 rate	
were	not	significantly	different	 in	 the	DOAC	and	warfarin	groups.	
Pericarditis	occurred	in	10	events	(34.5%)	and	17	(58.6%)	had	an	AF/
AT	 recurrence	 during	 their	 respective	 hospital	 stays	 (An	 example	
of	AF	recurrence	with	pericarditis	 is	shown	 in	Figure	2B).	None	of	
the	patients	required	surgical	treatment.	During	midterm	follow-	up	
(3.1	±	2.6	years),	27	events	were	free	from	AF	or	AT	(27/29;	93.1%,	
nine	events	with	antiarrhythmic	medication).
4.2 | Acute and midterm outcome in cardiac 
tamponade cases
While	 previous	 studies	 have	 reported	 frequency	 of	 cardiac	 tam-
ponade,	midterm	 outcomes	 are	 lacking.	 In	 this	 study,	 the	 overall	
acute	AF/AT	recurrence	rate	was	58.6%	(17/29).	In	19	events	that	
underwent	 complete	 ablation,	 the	 acute	 AF/AT	 rate	 was	 36.8%	
(7/19).	Conversely,	patients	 in	 the	 incomplete	ablation	group	had	
a	higher	AF/AT	recurrence	rate	(100.0%).	The	results	suggest	that	
complete	ablation	can	help	reduce	the	acute	recurrence	rate.	In	ad-
dition,	2	of	 the	19	events	 in	 the	 complete	 ablation	group	and	all	
 
Our study 
2018
Latchamsetty et al13 
2011
Bunch et al11 
2005
n = 29 n = 40 n = 15
Incidence of cardiac 
tamponade
29/2467	(1.18%) Not	mentioned 15/617	(2.4%)
Age	(years) 64.5	±	10.4 61.1	±	7.8 54	±	13
Male 22/29	(75.9%) 20/40	(50.0%) 10/15	(66.2%)
PAF 17/29	(58.6%) 28/40	(70.0%) 11/15	(73.3%)
Tamponade	by	atrial	
blood
7/19a	(36.8%) Not	mentioned 9/15	(60.0%)
Pericarditis 10/29	(34.5%) Not	mentioned 8/15	(53.3%)
Hospital	stay	(days) 11.6	±	7.1 Not	mentioned 6.8	±	4.8
Surgical	operation 0/29	(0.0%) 0/40	(0.0%) 0/15	(0.0%)
Death 0/29	(0.0%) 0/40	(0.0%) 0/15	(0.0%)
Anticoagulant	drug
Warfarin	use 21/29	(72.4%) 40/40	(100.0%) Not	mentioned
DOAC	use 7/29	(24.1%) 0/40	(0.0%) Not	mentioned
Ablation	procedure
RFCA 20/22b	(91.0%) 40/40	(100.0%) 15/15	(100.0%)
Balloon	ablation 2/22	(9.1%) 0/40	(0.0%) 0/15	(0.0%)
Acute	recurrence	in	
hospital
17/29	(58.6%) 20/40	(50.0%) 10/15	(66.7%)
Sinus	rhythm	
maintenance in 
midterm	F/U
27/29	(93.1%)	(9	events	
with	AAD;	
3.1	±	2.6	years	F/U)
Not	mentioned 7/9	(77.8%)	 
(1	patient	with	
AAD;	
1.5	±	1.1	years	
F/U)
AAD,	antiarrhythmic	drugs;	DOAC,	direct	oral	anticoagulants;	F/U,	follow-	up;	Not	mentioned,	the	
variable	was	not	mentioned	in	the	study;	PAF,	paroxysmal	atrial	fibrillation;	RFCA,	radiofrequency	
catheter	ablation;	Sinus	rhythm	maintenance	in	midterm	F/U,	Sinus	rhythm	maintenance	rate	of	pa-
tients	with	complete	procedure	in	midterm	follow-	up.
aThe	number	of	this	event	was	19	of	29,	as	the	drainage	was	not	performed	in	seven,	and	the	drain-
age	blood	type	could	not	be	evaluated	in	the	remaining	three	events.	
bThe	number	of	ablation	procedure	was	22,	as	cardiac	tamponade	occurred	before	ablation	proce-
dure	in	seven	events.	
TABLE  5 Comparison	with	previous	
literature	on	cardiac	tamponade
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10	 in	 the	 incomplete	group	required	 redo	sessions	after	blanking	
periods	of	3	months	and	most	events	maintained	sinus	rhythm	at	
midterm	follow-	up	(27/29,	93.1%,	with	antiarrhythmic	medication).	
This	 shows	 that	 even	 if	 tamponade	occurs,	 proper	 diagnosis	 and	
treatment	 could	 prevent	 serious	 complications	 such	 as	 death	 or	
other	unrecoverable	states.	If	the	patient	survives	the	acute	perio-
perative	period	and	the	repeat	procedures	are	performed	properly,	
sinus	rhythm	maintenance	could	be	expected,	similarly	 to	normal	
patients.	 This	 result	was	 similar	with	 a	 previous	 study	 by	 Bunch	
et al11	(Table	5),	which	reported	a	high	rate	of	sinus	rhythm	mainte-
nance	in	midterm	(7/9,	77.8%,	1	patient	with	antiarrhythmic	drug,	
1.5	±	1.1	years	follow-	up).	However,	it	bears	mentioning	that	these	
favorable	 results	were	achieved	at	a	high	volume	center	with	ex-
pert	electrophysiologists.
4.3 | Causes of cardiac tamponade
A	previous	paper	had	reported	that	steam	pops	can	cause	cardiac	tam-
ponade	during	ablation	of	ventricular	arrhythmias,	 and	 that	 surgical	
repair	was	often	needed.12	Although	cardiac	tamponade	attributable	
to	steam	pop	was	also	reported	during	AF	ablation,4	no	such	incidents	
occurred	in	this	study.	This	may	be	due	to	the	magnitude	of	energy	ap-
plied,	which	is	limited	to	35	W	at	our	institution.	Atrial	bleeding	could	
be	caused	by	injury	to	the	left	atrial	appendage,	left	atrial	roof,	or	PVs.	
In	 contrast,	 venous	 bleeding	occurs	 secondary	 to	 damage	 the	 right	
atrium,	right	ventricle,	or	coronary	sinus.	This	indicates	the	importance	
of	catheter	manipulation	in	the	right	side	of	the	heart	as	well	as	the	left	
side	during	AF	ablation	in	patients	on	anticoagulation.
4.4 | Anticoagulant therapy
The	 standard	 procedures	 for	 catheter	 ablation	 are	 changing	 and	
the	number	of	patients	requiring	AF	ablation	continues	to	increase	
worldwide.	 It	 is	 common	 to	 perform	AF	 ablation	while	 continuing	
anticoagulant	 therapy.	As	 long	as	 the	PT-	INR	 is	maintained	within	
the	 appropriate	 range,	 bleeding	 complications	 are	 rare,	 even	with	
warfarin treatment.12	All	our	patients	underwent	catheter	ablation	
while	on	anticoagulant	therapy.	This	study	is	the	first	report	to	de-
scribe	pericarditis	and	cardiac	tamponade	related	to	AF	ablation	in	
patients	receiving	anticoagulant	therapy,	including	DOAC.	Similar	to	
past	reports	of	warfarin	use	in11,13	cardiac	tamponade,	DOAC	may	
be	fully	manageable	if	proper	supports	are	given.
4.5 | Pericarditis with cardiac tamponade
A	 case	 of	 pericarditis	 complicated	 with	 cardiac	 tamponade	 was	
previously	 reported	by	Bunch	et	al11	 in	a	study	where	8	of	15	pa-
tients	 (53.3%)	 developed	 pericarditis	 (Table	5).	 In	 our	 study,	 10	
events	(10/29,	34.5%)	developed	pericarditis	after	cardiac	tampon-
ade	(Table	4).	The	events	with	pericarditis	required	 longer	hospital	
stays	(14.3	±	4.6	days).	Subsequent	pericarditis	was	less	frequent	in	
the	 group	 that	 received	 prophylactic	 treatment	 than	 in	 the	 group	
that	did	not	 (2/15,	13.3%	vs	8/14,	57.1%;	P	=	0.013).	The	cause	of	
pericarditis	 after	 cardiac	 tamponade	 is	 still	 unclear.	The	maximum	
value	of	serum	C-	reactive	protein	was	higher	in	the	pericarditis	group	
(12.32	±	7.8	 vs	 in	 nonpericarditis	 Group,	 3.71	±	3.0,	 P = 0.0002; 
Table	4),	presumably	caused	by	the	pericarditis	itself.	Although	there	
was	no	significant	difference	 in	 the	drainage	volume	between	 the	
two	groups	(680	±	485	mL	in	pericarditis	group	vs	272	±	124	mL	in	
nonpericarditis	group;	P	=	0.071),	pericarditis	tended	to	occurs	when	
the	volume	exceeded	600	mL.	 In	such	circumstances,	the	adminis-
tration	of	anti-	inflammatory	drugs	should	be	considered	to	prevent	
pericarditis.
4.6 | Delayed tamponade
Similarly	 to	 “Dressler	 syndrome”	 and	 “postcardiac	 injury	 syn-
drome,”	 late-	onset	 pericarditis	 after	 catheter	 ablation	 has	 been	
reported.14-16	The	onset	of	these	conditions	can	vary	from	within	
a	few	days	to	a	few	weeks	after	procedure.	Although	the	patho-
genesis	is	unclear,	inflammation	of	the	ablation	region	or	rupture	
of	 a	 hematoma	 on	 the	 pericardial	 side	 are	 possible	 causes	 of	
this	 rarecomplication.7	 In	 this	 study,	 only	 two	 events	 developed	
delayed	 tamponade	 (2/2467,	 0.081%).	 Both	 patients	 had	 been	
checked	 for	 excess	 pericardial	 fluid	 before	 discharge;	 therefore,	
we	suspect	that	the	pericardial	effusion	increased	during	the	post-
discharge	subacute	phase.	Even	at	several	weeks	after	the	proce-
dure,	 it	 is	necessary	 to	pay	attention	 to	changes	 in	 the	patient’s	
physical	condition	as	there	is	a	possibility,	albeit	low,	that	delayed	
tamponade	will	occur.
4.7 | Limitations
The	study	has	some	limitations.	First,	we	retrospectively	examined	
a	small	(29)	number	of	events	from	a	single	center.	Second,	the	AF/
AT	recurrences	were	diagnosed	based	on	the	patient’s	symptoms	
and	 regular	 follow-	up	 12-	lead	 ECGs,	 24-	h	 Holter	 monitoring,	 or	
event	recordings.	Recurrence	after	ablation	can	be	asymptomatic	
and	we,	 therefore,	may	 have	missed	 some	 cases.	 Third,	we	 used	
the	contact	force	system	in	only	10	events	because	of	insurance-	
related	 concerns.	 The	 use	 of	 a	 contact	 force	 system	may	 affect	
the	occurrence	of	cardiac	tamponade	as	 its	 incidence	may	be	de-
creased	 if	excessive	contact	 is	avoided.	Finally,	 the	rate	of	occur-
rence	of	cardiac	tamponade	depends	on	the	experience	of	both	the	
operator	and	the	institute.	Thus,	in	a	different	setting,	the	results	
may differ.
5  | CONCLUSION
Cardiac	tamponade	is	a	serious	complication	of	the	catheter	ablation	
procedure	for	AF,	and	acute	AT/AF	recurrence	and	pericarditis	are	
quite	common.	 If	 the	ablation	procedure	can	be	completed	before	
the	occurrence	of	 cardiac	 tamponade,	 or	 a	 repeat	 ablation	proce-
dure	scheduled	later,	the	midterm	outcomes	of	AF	ablation	may	be	
unaffected.
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